Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason K Perry

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Bioorganic & Medicinal Chemistry Letters|December 20, 2017
Discovery of potent and selective inhibitors of calmodulin-dependent kinase II (CaMKII)Dmitry O Koltun, Eric Q Parkhill, Rao Kalla, et al.
Nature|February 1, 2023
Structural basis for substrate selection by the SARS-CoV-2 replicaseBrandon F Malone, Jason K Perry, Paul Dominic B Olinares, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2019
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi<sup>®</sup> and Epclusa<sup>®</sup>John O Link, James G Taylor, Alejandra Trejo-Martin, et al.
Viruses|April 27, 2024
No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE TrialsCharlotte Hedskog, Christoph D Spinner, Ulrike Protzer, et al.
Cell Reports|July 16, 2020
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in MiceAndrea J Pruijssers, Amelia S George, Alexandra Schäfer, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in miceAndrea J Pruijssers, Amelia S George, Alexandra Schäfer, et al.
Science Translational Medicine|May 22, 2024
The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronavirusesDavid R Martinez, Fernando R Moreira, Nicholas J Catanzaro, et al.
Journal of Medicinal Chemistry|July 17, 2024
Discovery of GS-7682, a Novel 4'-Cyano-Modified <i>C</i>-Nucleoside Prodrug with Broad Activity against Pneumo- and Picornaviruses and Efficacy in RSV-Infected African Green MonkeysDustin S Siegel, Hon C Hui, Jared Pitts, et al.
Nature Communications|July 11, 2025
Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeysJared Pitts, J Lizbeth Reyes Zamora, Savrina Manhas, et al.
Journal of Medicinal Chemistry|October 1, 2025
Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure ProphylaxisEda Canales, Winston Tse, Scott D Schroeder, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Bioorganic & Medicinal Chemistry Letters|December 20, 2017
Discovery of potent and selective inhibitors of calmodulin-dependent kinase II (CaMKII)Dmitry O Koltun, Eric Q Parkhill, Rao Kalla, et al.
Nature|February 1, 2023
Structural basis for substrate selection by the SARS-CoV-2 replicaseBrandon F Malone, Jason K Perry, Paul Dominic B Olinares, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2019
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi<sup>®</sup> and Epclusa<sup>®</sup>John O Link, James G Taylor, Alejandra Trejo-Martin, et al.
Viruses|April 27, 2024
No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE TrialsCharlotte Hedskog, Christoph D Spinner, Ulrike Protzer, et al.
Cell Reports|July 16, 2020
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in MiceAndrea J Pruijssers, Amelia S George, Alexandra Schäfer, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in miceAndrea J Pruijssers, Amelia S George, Alexandra Schäfer, et al.
Science Translational Medicine|May 22, 2024
The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronavirusesDavid R Martinez, Fernando R Moreira, Nicholas J Catanzaro, et al.
Journal of Medicinal Chemistry|July 17, 2024
Discovery of GS-7682, a Novel 4'-Cyano-Modified <i>C</i>-Nucleoside Prodrug with Broad Activity against Pneumo- and Picornaviruses and Efficacy in RSV-Infected African Green MonkeysDustin S Siegel, Hon C Hui, Jared Pitts, et al.
Nature Communications|July 11, 2025
Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeysJared Pitts, J Lizbeth Reyes Zamora, Savrina Manhas, et al.
Journal of Medicinal Chemistry|October 1, 2025
Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure ProphylaxisEda Canales, Winston Tse, Scott D Schroeder, et al.
Pageof 4